3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
12
Lymphoma, Non-Hodgkin
11
Lymphoma, Follicular
7
Multiple Myeloma
6
Lymphoma
6
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, B-Cell, Marginal Zone
4
Leukemia
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms, Plasma Cell
3
Lymphoma, Mantle-Cell
3
Lymphoma, B-Cell
3
Waldenstrom Macroglobulinemia
2
Leukemia, Myeloid, Acute
2
Burkitt Lymphoma
2
Sezary Syndrome
1
Pancreatic Neoplasms
1
Neurologic Manifestations
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphatic Diseases
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphoid
1
Leukemia, Hairy Cell
1
Intraocular Lymphoma
1
Hematologic Neoplasms
1
Brain Neoplasms
1
Interventions
Rituximab
4
Etoposide
3
Cyclophosphamide
3
cobomarsen
2
Vincristine
2
Prednisone
2
Ifosfamide
2
Doxorubicin
2
Carboplatin
2
Brentuximab Vedotin
2
ponatinib
1
pomalidomide
1
ibritumomab tiuxetan
1
fludarabine
1
dacetuzumab
1
Vorinostat
1
Melphalan
1
Imatinib Mesylate
1
Everolimus
1
DTRMWXHS-12
1
Cytarabine
1
Carmustine
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphatic Diseases
×
Bendamustine Hydrochloride
×
Clear all
NCT02499627
2021-05-27
FIL-BBV
Fondazione Italiana Linfomi - ETS
Phase 2
Terminated
43 enrolled